Samrat Pharmachem Limited (BOM:530125)
India · Delayed Price · Currency is INR 371.45
+6.05 (1.66%)
At close: Jul 15, 2025
Samrat Pharmachem Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 2,859 | 2,816 | 3,106 | 2,218 | 1,790 | Upgrade |
Other Revenue | - | 0.57 | 0.99 | 1.07 | 1.49 | Upgrade |
| 2,859 | 2,816 | 3,107 | 2,219 | 1,792 | Upgrade | |
Revenue Growth (YoY) | 1.50% | -9.37% | 40.06% | 23.83% | 30.28% | Upgrade |
Cost of Revenue | 2,667 | 2,703 | 2,779 | 1,899 | 1,642 | Upgrade |
Gross Profit | 191.14 | 113.21 | 328.8 | 319.58 | 149.22 | Upgrade |
Selling, General & Admin | 22.21 | 23.62 | 20.51 | 18.37 | 15.77 | Upgrade |
Other Operating Expenses | 66.52 | 64.46 | 67.99 | 57.48 | 40.73 | Upgrade |
Operating Expenses | 95.28 | 94.55 | 94.94 | 81.8 | 63.7 | Upgrade |
Operating Income | 95.87 | 18.66 | 233.86 | 237.78 | 85.52 | Upgrade |
Interest Expense | -6.74 | -5.53 | -9.3 | -3.64 | -9.37 | Upgrade |
Interest & Investment Income | - | 3.05 | 2 | 1.38 | 0.86 | Upgrade |
Currency Exchange Gain (Loss) | - | 0.32 | 1.53 | 0.6 | - | Upgrade |
Other Non Operating Income (Expenses) | 9.73 | -1.35 | -3.02 | -0.18 | -3.4 | Upgrade |
EBT Excluding Unusual Items | 98.86 | 15.15 | 225.07 | 235.94 | 73.6 | Upgrade |
Gain (Loss) on Sale of Investments | - | 9.87 | 0.23 | 0.08 | - | Upgrade |
Gain (Loss) on Sale of Assets | - | 0.18 | - | -0.23 | - | Upgrade |
Other Unusual Items | - | - | - | - | -0.18 | Upgrade |
Pretax Income | 98.86 | 25.2 | 225.3 | 236.01 | 73.44 | Upgrade |
Income Tax Expense | 27.74 | 3.58 | 59 | 64.16 | 20.11 | Upgrade |
Net Income | 71.12 | 21.63 | 166.31 | 171.85 | 53.33 | Upgrade |
Net Income to Common | 71.12 | 21.63 | 166.31 | 171.85 | 53.33 | Upgrade |
Net Income Growth | 228.87% | -87.00% | -3.23% | 222.22% | 25.88% | Upgrade |
Shares Outstanding (Basic) | 3 | 3 | 3 | 3 | 3 | Upgrade |
Shares Outstanding (Diluted) | 3 | 3 | 3 | 3 | 3 | Upgrade |
Shares Change (YoY) | -0.00% | - | - | - | - | Upgrade |
EPS (Basic) | 23.02 | 7.00 | 53.83 | 55.62 | 17.26 | Upgrade |
EPS (Diluted) | 23.02 | 7.00 | 53.83 | 55.62 | 17.26 | Upgrade |
EPS Growth | 228.89% | -87.00% | -3.23% | 222.25% | 25.89% | Upgrade |
Free Cash Flow | -105.99 | 87.45 | -108.96 | 161.98 | 20.69 | Upgrade |
Free Cash Flow Per Share | -34.30 | 28.30 | -35.27 | 52.42 | 6.70 | Upgrade |
Dividend Per Share | 1.000 | 1.000 | 1.000 | 1.000 | - | Upgrade |
Gross Margin | 6.69% | 4.02% | 10.58% | 14.40% | 8.33% | Upgrade |
Operating Margin | 3.35% | 0.66% | 7.53% | 10.72% | 4.77% | Upgrade |
Profit Margin | 2.49% | 0.77% | 5.35% | 7.75% | 2.98% | Upgrade |
Free Cash Flow Margin | -3.71% | 3.10% | -3.51% | 7.30% | 1.16% | Upgrade |
EBITDA | 102.42 | 25.12 | 240.28 | 243.71 | 90.44 | Upgrade |
EBITDA Margin | 3.58% | 0.89% | 7.73% | 10.98% | 5.05% | Upgrade |
D&A For EBITDA | 6.55 | 6.46 | 6.42 | 5.94 | 4.93 | Upgrade |
EBIT | 95.87 | 18.66 | 233.86 | 237.78 | 85.52 | Upgrade |
EBIT Margin | 3.35% | 0.66% | 7.53% | 10.72% | 4.77% | Upgrade |
Effective Tax Rate | 28.06% | 14.19% | 26.19% | 27.19% | 27.38% | Upgrade |
Revenue as Reported | 2,868 | 2,830 | 3,111 | 2,224 | 1,795 | Upgrade |
Advertising Expenses | - | 1.43 | 1.72 | 0.62 | 0.79 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.